206 related articles for article (PubMed ID: 36906716)
1. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
Wang M; Yue S; Yang Z
Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
[TBL] [Abstract][Full Text] [Related]
2. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma.
Zhang Q; Luo Y; Zhang S; Huang Q; Liu G
Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747
[TBL] [Abstract][Full Text] [Related]
3. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
4. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
5. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
Tian Y; Wen F; Wang S; Lv N
Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
[TBL] [Abstract][Full Text] [Related]
6. MiR-29a-5p inhibits proliferation and invasion and induces apoptosis in endometrial carcinoma via targeting TPX2.
Jiang T; Sui D; You D; Yao S; Zhang L; Wang Y; Zhao J; Zhang Y
Cell Cycle; 2018; 17(10):1268-1278. PubMed ID: 29888640
[TBL] [Abstract][Full Text] [Related]
7. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Lu X; Jing L; Liu S; Wang H; Chen B
Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192
[TBL] [Abstract][Full Text] [Related]
8.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
9. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
[TBL] [Abstract][Full Text] [Related]
10.
Wang C; Yin Y; Sun Z; Wang Y; Li F; Wang Y; Zhang Z; Chen X
Dis Markers; 2022; 2022():2334338. PubMed ID: 36479043
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
12. Construction of a prognostic model of luteolin for endometrial carcinoma.
Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
[TBL] [Abstract][Full Text] [Related]
13. The Circadian Gene NPAS2 Act as a Putative Tumor Stimulative Factor for Uterine Corpus Endometrial Carcinoma.
Zheng X; Lv X; Zhu L; Xu K; Shi C; Cui L; Ding H
Cancer Manag Res; 2021; 13():9329-9343. PubMed ID: 34992456
[TBL] [Abstract][Full Text] [Related]
14. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
[TBL] [Abstract][Full Text] [Related]
15. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.
Sun Y; Zhang K; Wang T; Zhao S; Gao C; Xue F; Wang Y
Sci Rep; 2024 Mar; 14(1):6134. PubMed ID: 38480789
[TBL] [Abstract][Full Text] [Related]
17. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
18. Long non‑coding RNA BLACAT2/miR‑378a‑3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma.
Zhang C; Wang R; Li M; Yang Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052291
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analysis of ESRRA in Endometrial Cancer.
Wang S; Huo X
Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
[TBL] [Abstract][Full Text] [Related]
20. A novel risk prediction model of pyroptosis-related genes for the prognosis and immunotherapy response of endometrial cancer.
Liu ZS; Jing CL
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2259-2278. PubMed ID: 35442481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
